Jeremy Brett Sokolove, Chief Medical Officer of Vor Biopharma Inc., filed a Form 4 on November 4, 2026, disclosing that 1,917 shares of common stock were withheld on November 2, 2026, to cover tax obligations tied to the vesting of restricted stock units.

Key Highlights

  • Reporting person: Jeremy Brett Sokolove, Chief Medical Officer of Vor Biopharma Inc. (NASDAQ:VOR)
  • Transaction date: November 2, 2026
  • Shares withheld: 1,917 shares of common stock, disposed of (Code F) at $19.25 per share
  • Purpose of withholding: To satisfy tax withholding obligations related to vesting of restricted stock units granted on November 1, 2025
  • Beneficial ownership following transaction: 25,983 shares of common stock held directly

Sokolove RSU Vesting Triggers Tax Withholding at Vor Biopharma

According to the filing, the transaction recorded is a share withholding by Vor Biopharma Inc. to satisfy tax obligations arising from the vesting of restricted stock units originally granted to Sokolove on November 1, 2025. The transaction code reported is "F," which the filing associates with shares withheld by the company for tax purposes rather than an open-market sale.

The filing reports that 1,917 shares were disposed of at a price of $19.25 per share on November 2, 2026. Following this transaction, Sokolove directly holds 25,983 shares of Vor Biopharma common stock, according to the disclosure. No derivative securities were reported in Table II of the filing.

The Form 4 was signed by Adi Osovsky as Attorney-in-Fact and filed on November 4, 2026. The filing was submitted by one reporting person and is not an amendment to a prior filing.

What Was Disclosed

Vor Biopharma's Chief Medical Officer Jeremy Brett Sokolove disclosed the withholding of 1,917 common shares at $19.25 on November 2, 2026, for RSU-related tax obligations, leaving him with 25,983 directly held shares.